2026-01-22 01:04Business Overview - Lizhu Biopharmaceuticals operates three main business segments: autoimmune, reproductive, and vaccine fields [2][3] - The core product in the autoimmune field, Lakanqita monoclonal antibody, has shown superior efficacy in clinical trials compared to competitors [4][5] Autoimmune Field - Lakanqita monoclonal antibody targets IL-17A/F dual sites, with a PASI100 response rate of 49.5% in clinical trials, outperforming the control group at 40.2% [4] - The product is expected to receive approval by the end of 2026, with significant market potential due to its unique characteristics [5] Reproductive Field - The recombinant human follicle-stimulating hormone (r-FSH) injection is anticipated to be approved within the year, reinforcing the company's leadership in assisted reproduction [3] Vaccine Field - The quadrivalent recombinant protein influenza vaccine is the first of its kind with an adjuvant, having completed Phase I trials and expected to enter Phase II in March [3] International Expansion Strategy - The company adopts a dual-track strategy for international expansion, focusing on licensing out innovative pipelines and direct exports to emerging markets [5][6] - Key markets include Southeast Asia and South America, with Vietnam and Brazil as strategic hubs for regulatory advantages and market growth [6] Cardiovascular Pipeline - H001, an oral direct thrombin inhibitor, is the fastest progressing project in its category, aimed at preventing venous thromboembolism (VTE) post-orthopedic surgeries [7] - The product has shown comparable efficacy to standard therapies and is preparing for Phase III trials [8] GnRH Pipeline - The GnRH pipeline covers all related indications and various formulations, making it the most comprehensive in China [9] - Key products include leuprolide with multiple formulations expected to launch soon, enhancing market presence [9] Chemical Preparation Segment - The chemical preparation segment generated revenue of 4.72 billion CNY, accounting for 51.8% of the company's total revenue in the first nine months of 2025 [10][11] - Growth drivers include product upgrades, innovation, and a focus on core therapeutic areas [11][12]